Blood progesterone levels throughout cycle remain low during the follicular phase, rise sharply after ovulation, and peak in the mid-luteal window before falling to trigger menstruation.
The Verdict
Biological Origin and Secretion Across Cycle Phases
Progesterone is a steroid hormone produced primarily by the ovarian corpus luteum after a follicle ruptures to release an egg. Before ovulation, circulating progesterone remains barely detectable in the bloodstream during the follicular phase, with baseline production rates of roughly 1 mg per day.
Approximately one day prior to ovulation, synthesis begins to climb. Once the follicle releases a mature ovum, its theca and granulosa cells transform into the corpus luteum under the direction of luteinizing hormone. Daily hormone production escalates to approximately 25 mg per day in the mid-luteal phase, where progesterone converts the estrogen-primed uterine mucosa into a secretory tissue rich in glands.
Peak progesterone concentrations occur roughly 8 to 9 days after ovulation, coinciding with maximum corpus luteum vascularization. If fertilization does not take place within 14 days following ovulation, the corpus luteum stops secreting hormones, regresses into a fibrous scar known as the corpus albicans, and the subsequent drop in circulating progesterone causes the uterine lining to shed as menstrual bleeding.
Phase-Specific Reference Values Across Major Laboratories
Reference intervals for progesterone levels throughout cycle vary considerably between commercial and academic testing facilities. Reference intervals are not interchangeable between laboratories because automated immunoassay platforms carry systematic analytical bias. Readers must compare their personal blood test numbers against the specific reference range printed on their own laboratory report.
The table below details reference ranges established by Labcorp and the University of Washington Department of Laboratory Medicine, alongside research cohort medians reported by Anckaert and colleagues. Conversion between mass units and molar units uses the derived factor of 1 ng/mL equating to 3.18 nmol/L, calculated from progesterone molecular weight of 314.5 daltons.
| Cycle Phase | Labcorp Range (ng/mL) | University of Washington Range (ng/mL) | Research Cohort Median (nmol/L) |
|---|---|---|---|
| Follicular phase | 0.1 to 0.9 (0.3 to 2.9 nmol/L) | 0.4 to 1.4 (1.3 to 4.5 nmol/L) | 0.212 (0.07 ng/mL) |
| Ovulatory / Mid-cycle | 0.1 to 12.0 (0.3 to 38.2 nmol/L) | 0.6 to 2.0 (1.9 to 6.4 nmol/L) | 1.81 (0.57 ng/mL) |
| Mid-luteal phase | 1.8 to 23.9 (5.7 to 76.0 nmol/L) | 6.0 to 24.0 (19.1 to 76.3 nmol/L) | 39.2 (12.3 ng/mL) |
| Postmenopausal | 0.0 to 0.1 (0.0 to 0.3 nmol/L) | <1.2 (<3.8 nmol/L) | Not reported in cohort |
Analytical Discrepancies Between Automated Immunoassays
Different clinical analyzers yield conflicting numerical values for identical blood samples because automated immunoassays exhibit variable degrees of calibration bias. In an evaluation of cycle-monitored reference intervals published in Practical Laboratory Medicine, Anckaert and co-authors observed that automated immunoassays for estradiol and progesterone carry variable bias, necessitating platform-specific reference thresholds.
These technical discrepancies appear directly in the major laboratory handbooks. Labcorp utilizes an electrochemiluminescence immunoassay on the Roche cobas system, setting its female follicular upper reference limit at 0.9 ng/mL. The University of Washington clinical laboratory relies on a chemiluminescent platform that extends the mid-follicular upper limit to 1.4 ng/mL.
Disagreement is even more pronounced around mid-cycle and the luteal boundary. Labcorp defines the ovulatory window broadly from 0.1 up to 12.0 ng/mL, whereas University of Washington caps its mid-cycle range at 2.0 ng/mL. At the lower luteal boundary, Labcorp considers 1.8 ng/mL within range, while the University of Washington sets its mid-luteal threshold at 6.0 ng/mL. A reading of 4.5 ng/mL would be classified as luteal on one platform and sub-luteal on another.
Cycle Day Timing and the Mid-Luteal Window
The traditional day 21 blood draw is a convention based strictly on an idealized 28-day cycle. Clinical guidelines from the National Institute for Health and Care Excellence (NICE NG257) recommend measuring serum progesterone in the mid-luteal phase to confirm ovulation, noting that day 21 applies only to 28-day rhythms.
Counting forward from cycle day 1 causes frequent misclassification because the follicular phase varies between 10 to 16 days, whereas the luteal phase remains relatively constant at approximately 14 days. If an individual ovulates on cycle day 18, a day-21 draw captures the early post-ovulatory rise rather than the mid-luteal peak. For a complete analysis of how cycle timing interacts with broader hormone panels, see our guide to the perimenopause biomarker panel. The practical instruction is therefore to count backward about 7 days from the expected period, which NICE illustrates with day 28 of a 35-day cycle.
Published Criteria for Ovulation Confirmation
Medical guidelines and published studies offer divergent numerical thresholds to verify whether ovulation has occurred. No universal consensus threshold exists across clinical practice, and diagnostic criteria vary depending on study design and analytical method.
In a diagnostic study of 102 women across 260 cycles published in Steroids, Leiva and colleagues determined that a single random serum progesterone level of 5 ng/mL or higher confirmed ovulation with 98.4% specificity and 89.6% sensitivity. By comparison, earlier clinical literature from Petsos and colleagues in 1987 used a cutoff of 10 ng/mL (32 nmol/L), though the authors noted in their text that this number was chosen arbitrarily to separate adequate from inadequate corpus luteum function.
Other diagnostic frameworks avoid fixed concentration cutoffs altogether. A classic British Medical Journal paper by Wathen and colleagues proposed evaluating luteal progesterone as a ratio against each laboratory's own follicular median, using thresholds of two and four times the follicular median to identify ovulatory and normal luteal function. Meanwhile, formal national guidelines such as NICE NG257 recommend measuring mid-luteal progesterone but publish no specific concentration cutoff.
| Source | Proposed Threshold | Methodology or Stated Accuracy | Clinical Scope |
|---|---|---|---|
| Leiva et al. (2015) | ≥5.0 ng/mL (15.9 nmol/L) | Specificity 98.4%, Sensitivity 89.6% | Ovulation confirmation in natural cycles |
| Petsos et al. (1987) | 10.0 ng/mL (32.0 nmol/L) | Arbitrary cutoff; 1 of 11 below cutoff was ovulatory | Discrimination of corpus luteum adequacy |
| Wathen et al. (1984) | 2× and 4× follicular median | Ratio-based rule of thumb relative to lab baseline | Ovulatory vs anovulatory cycle screening |
| NICE NG257 (2013) | No numeric cutoff published | Guideline recommends mid-luteal blood test | Investigation of fertility management |
Hormone Pulsatility and Single-Draw Evaluation Limits
A single serum progesterone measurement cannot reliably gauge the health or adequacy of the corpus luteum because secretion occurs in rapid pulses. Progesterone release is episodic and closely synchronized with pulses of pituitary luteinizing hormone throughout the second half of the cycle.
In a landmark study published in the Journal of Clinical Investigation, Filicori and co-investigators sampled blood every 10 minutes over 24-hour periods in normal female volunteers. In the mid- and late-luteal phases, plasma progesterone concentrations swung between 2.3 and 40.1 ng/mL within the course of minutes in the same individual. These dramatic spikes followed luteinizing hormone pulses at lag intervals of 25 to 55 minutes, creating a 17-fold difference between daily nadirs and peaks.
Filicori observed that the early luteal phase displayed relatively stable secretion without episodic fluctuations. In contrast, mid- and late-luteal secretory bursts were so pronounced that the authors concluded single mid- and late-luteal estimations do not accurately reflect corpus luteum adequacy. Filicori recorded the full 2.3 to 40.1 ng/mL swing within a single 24-hour study in the same woman, with individual increments following luteinizing hormone pulses within the hour.
Clinical Assessment of Low Mid-Luteal Results
A low progesterone result drawn during the second half of a menstrual cycle does not automatically prove anovulation. Because the follicular phase varies widely from 10 to 16 days while the luteal phase remains relatively fixed, an unexpected low concentration most commonly reflects incorrect calendar timing.
If an individual ovulates later than day 14 in a given month, a blood draw scheduled on calendar day 21 lands in the pre-ovulatory phase, where progesterone values physiologically remain under 1.0 ng/mL. Attributing a low reading to an anovulatory cycle without serial monitoring or ultrasound correlation risks substantial misdiagnosis.
To prevent diagnostic errors, clinical guidelines from NICE (recommendation 1.18.8) advise repeating blood tests weekly until menstruation begins for individuals with prolonged or irregular cycles. A series of measurements confirms whether delayed ovulation occurred later in the cycle, providing far more clinical utility than treating an isolated low number as conclusive.
Specimen Requirements and Testing Logistics
Serum blood collection remains the clinical standard for quantitative progesterone assessment. Commercial laboratories collect samples using red-top tubes, gel-barrier tubes, or green-top lithium heparin tubes, requiring a minimum volume of 0.7 mL serum or plasma. Blood tubes must be centrifuged promptly because prolonged contact of serum with certain gel barriers can alter measured steroid concentrations.
Alternative specimen formats carry diagnostic limitations. Home urine test strips detect pregnanediol glucuronide (PdG), the primary urinary breakdown product of progesterone. In a feasibility pilot study evaluating home PdG test strips across 34 cycles, Bouchard and colleagues reported positive test confirmation in 82.4% of ovulatory cycles at a 5 µg/mL threshold, but in only 59% at a 7 µg/mL threshold. Salivary testing carries even less validity; consensus guidance from the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Reproductive Medicine (ASRM) states that salivary testing does not offer accurate or precise assessment of hormone levels, and notes that no FDA-approved salivary or urinary tests exist for steroid hormone measurement.
Standard laboratory preparation involves minimal restrictions. Commercial facilities do not list a fasting requirement for progesterone testing. However, Labcorp instructs patients taking high-dose biotin (vitamin B7) supplements to discontinue them for at least 72 hours prior to collection. Biotin concentrations found in hair and nail products can reach 5 to 10 mg (up to 650 times the recommended dietary intake), creating positive or negative analytical interference depending on the immunoassay architecture used.
| Testing Modality | Specimen Type | US Cash Price (Checked September 2026) |
|---|---|---|
| Labcorp OnDemand Progesterone Test | Serum / Plasma (Blood draw) | $89.00 |
| Quest Diagnostics Progesterone Test | Serum (Blood draw) | $89.00 |
| Proov Fertility Test Kit (Quest Consumer) | Urine test strips (PdG metabolite) | $29.00 |
Diagnostic Limitations and Clinical Boundaries
A quantitative progesterone test cannot diagnose the underlying cause of infertility or verify early pregnancy. Labcorp explicitly notes on its patient-facing test directory that a progesterone lab test does not diagnose or determine the cause of infertility, but serves only as an initial step in assessing whether ovulation took place. Pregnancy evaluation requires measuring human chorionic gonadotropin (hCG), which detects trophoblastic tissue rather than corpus luteum steroidogenesis.
Clinical interest historically focused on diagnosing luteal phase deficiency (LPD), defined as an abnormal luteal phase length of 10 days or fewer. However, formal practice committee opinions from the ASRM and the Society for Reproductive Endocrinology and Infertility (SREI) state that luteal phase deficiency has not been proven to be an independent clinical entity causing infertility or recurrent pregnancy loss. Diagnostic criteria remain controversial because single blood draws cannot capture pulsatile secretion, and the ASRM and SREI committee opinion records that the controversy extends to whether the condition can be diagnosed accurately at all.
Endocrine conditions and medications also alter test interpretation. Progesterone rises in congenital adrenal hyperplasia due to 21-hydroxylase, 17-hydroxylase, or 11-beta-hydroxylase enzyme deficiencies. Conversely, concentrations drop in primary or secondary hypogonadism. Combined oral contraceptives suppress pituitary release of luteinizing hormone and follicle-stimulating hormone, preventing ovulation entirely and eliminating the post-ovulatory progesterone surge.
This test is not suitable for individuals taking hormonal contraceptives or those seeking a standalone diagnosis for fertility challenges. Our assessment of single blood draws would change if continuous, non-invasive hormone monitoring technology demonstrated accurate correlation with pulsatile serum peaks in peer-reviewed clinical trials.
Frequently Asked Questions
Does a progesterone test require fasting?
Commercial diagnostic laboratories do not list a fasting requirement for serum progesterone blood tests. You can eat and drink normally prior to your appointment. However, testing facilities recommend discontinuing high-dose biotin supplements for at least 72 hours before sample collection, as excessive vitamin B7 can interfere with competitive immunoassay instruments. If your blood draw includes metabolic markers or fasting lipid panels, follow the specific fasting instructions required for those companion tests.
Can a progesterone test be done on day 20, 22 or 23?
A progesterone test can be performed on day 20, 22, or 23 if that date aligns with your personal mid-luteal window. The conventional day-21 rule applies only to an idealized 28-day cycle with ovulation occurring on day 14. Because the corpus luteum reaches peak progesterone secretion roughly 8 to 9 days after ovulation, testing on day 22 or 23 is physiologically appropriate for someone who ovulated on day 14 or 15. The most reliable scheduling method is counting backward roughly 7 days from your expected period.
Does a progesterone test confirm ovulation?
A mid-luteal blood test provides strong evidence of ovulation, but medical authorities disagree on the exact numerical cutoff. Research by Leiva and colleagues demonstrated that a serum progesterone concentration of 5.0 ng/mL or higher confirmed ovulation with 98.4% specificity and 89.6% sensitivity. Earlier publications used an arbitrary threshold of 10.0 ng/mL, while other researchers suggest comparing results against the laboratory's baseline follicular median. National clinical guidelines from NICE recommend the test to verify ovulatory activity without imposing a rigid numerical cutoff.
Is a progesterone test blood or urine?
A clinical quantitative progesterone test requires a venous blood draw to analyze serum or plasma. Blood testing provides an exact numerical concentration measured in nanograms per milliliter or nanomoles per liter. At-home urine test strips measure pregnanediol glucuronide, a downstream liver breakdown metabolite of progesterone, rather than active hormone. While urine metabolite strips offer home convenience, ACOG and ASRM consensus statements emphasize that there are currently no FDA-approved urinary or salivary steroid hormone tests for diagnostic medical evaluation.
What does a progesterone level of zero mean?
A progesterone reading near zero, reported as 0.0 or below the assay detection threshold, indicates that an active corpus luteum was not present when the blood was drawn. This baseline reading is normal during the pre-ovulatory follicular phase, after menopause, or while using hormonal contraceptives that suppress ovulation. In someone attempting mid-luteal testing, a near-zero concentration usually means the test was mistimed before ovulation occurred rather than confirming true physiological anovulation.
What does a progesterone level greater than 40 mean?
A progesterone reading above 40 ng/mL exceeds standard mid-luteal reference intervals, where commercial upper bounds generally sit between 23.9 and 24.0 ng/mL. However, physiological studies evaluating blood samples drawn every 10 minutes documented mid-luteal peaks reaching 40.1 ng/mL in healthy ovulatory volunteers during natural secretory pulses. A reading above 40 ng/mL sits inside the range Filicori recorded in healthy ovulatory volunteers, so a single high value is not self-evidently abnormal. Labcorp also lists progesterone as increased in congenital adrenal hyperplasia, and should be evaluated by a physician alongside clinical history.
How much does a progesterone test cost?
A direct-to-consumer quantitative progesterone blood test costs $89.00 at major national diagnostic providers (checked September 2026). Both Labcorp OnDemand and Quest Diagnostics list serum blood tests at $89.00; Labcorp OnDemand states results in 1 day from when the sample arrives at its lab, and Quest does not publish a turnaround figure on its consumer listing. Over-the-counter home urine test kits measuring the pregnanediol glucuronide metabolite, such as the Proov kit available through Quest, cost $29.00. Insurance coverage depends on clinical coding and whether a physician orders testing for menstrual or reproductive evaluation.
Do at-home progesterone test strips work?
At-home test strips detect pregnanediol glucuronide, a urinary metabolite of progesterone, rather than circulating serum hormone. A clinical feasibility pilot study found that home urine test strips confirmed ovulation in 82.4% of cycles at a 5 µg/mL cutoff, but dropped to 59% accuracy at a 7 µg/mL cutoff. Medical societies including ACOG note that urine metabolite tests lack FDA approval for clinical steroid hormone diagnosis, meaning they serve as rough home tracking aids rather than clinical substitutes for laboratory venipuncture.